A New White Paper about Psychedelic Medicine and it's Economics

A new white paper with my colleagues at BrainFutures hit the press!

This is not exactly the forum for press releases. I have a really hard time with stale, academic writing. Which is of course why I do so much of it?

OK, clearly I have a problem. So here's the story: Psychedelic medicine is exciting. But it's not here yet. And, unfortunately, the market forces that are necessary to get psychedelic medicine to the world are complicated. Even if we had a cure for depression, tomorrow, that worked 100% of the time, I'm still not sure if we can get it paid for in a decade. I've been hustling for more appropriate payment for transcranial magnetic stimulation for years, and we still have a long way to go. Healthcare payments are complicated. One of the steps to getting a new treatment modality adopted is to understand why there might be difficulties in that process. As part of those endeavors, I have worked with my friends and colleagues at BrainFutures, a 501(c)(3) nonprofit, in order to better understand the landscape. Today, BrainFutures and Colleague…